5 years ago

Development of Substrate-Derived Sirtuin Inhibitors with Potential Anticancer Activity

Development of Substrate-Derived Sirtuin Inhibitors with Potential Anticancer Activity
Linda Baldus, Constance Chollet, Michael Lammers, Nora Kuhlmann, Ines Neundorf
RhoGDIα is a key regulator of Rho proteins, coordinating their GTP/GDP and membrane/cytosol cycle. Recently, it was demonstrated by quantitative mass spectrometry that RhoGDIα is heavily targeted by post-translational lysine acetylation. For one site in its N-terminal domain, namely K52, we reported earlier that acetylation completely switches off RhoGDIα function. Herein we show that K52-acetylated RhoGDIα is specifically deacetylated by the sirtuin deacetylase Sirt2. We show that acetylation at K52 decelerates cervical cancer cell proliferation, suggesting RhoGDIα acetylation to be a promising therapeutic target. We demonstrate that treatment of cervical cancer cells with a RhoGDIα-derived K52-trifluoroacetylated, substrate-derived peptidic sirtuin inhibitor severely impairs cell proliferation. Finally, we conclude that the potency of substrate-derived sirtuin inhibitors depends on structural features, the substrate-derived amino acid sequence as a determinant for selectivity, as well as the presence of an acetyl-lysine analogue to increase its potency. These data reveal a prospective therapeutic potential for novel substrate-derived sirtuin inhibitors. Substrate-based sirtuin inhibitors: Sirtuin deacetylases play important roles in the development of severe diseases such as cancer and neurodegenerative disorders. Therapeutics that tackle sirtuin activity must be potent and selective. We describe how sirtuin inhibitors can be designed based on identified non-histone substrates, taking RhoGDIα as an example. We show that using substrate-based peptides carrying an acetyl-lysine analogue, such as trifluoroacetyl-lysine, in combination with cell-penetrating peptides is a promising strategy to develop selective and potent sirtuin inhibitors for therapeutic applications.

Publisher URL: http://onlinelibrary.wiley.com/resolve/doi

DOI: 10.1002/cmdc.201700414

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.